血栓溶解薬市場：製品別、適応症別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Allied Market Researchが発行した新しいレポートによると、血栓溶解薬市場は2022年に286億米ドルと評価され、2023年から2032年にかけてCAGR 8.2%で成長し、2032年には600億米ドルに達すると推定されています。

血栓溶解薬は、血栓破壊薬または線維素溶解薬としても知られ、血栓症と呼ばれる病状の血栓を溶解するために使用される薬剤です。血栓症は、血管内に血栓が形成され、血液の流れが阻害されることで発症します。TPAは脳への血流の遮断または中断を引き起こしている血栓を破壊するために使用される血栓溶解薬または血栓破壊薬で、脳の患部への血流の回復を助けます。ヘパリン、ワルファリン、ダビガトラン、アピキサバン、リバーロキサバンなどの抗凝固薬は、血液をサラサラにして血栓の溶解を助ける薬です。

心血管疾患の治療ガイドラインでは、特定の病態において血栓溶解薬の使用が頻繁に必要とされています。診断方法が改善され、心血管疾患の徴候や症状に対する認識が高まった結果、早期発見・早期治療が可能になりました。将来の危害を防ぐために、早期介入には通常、血栓溶解薬の使用が含まれます。全体として、心血管障害の有病率の上昇は、治療法の選択肢の革新と意識の高まりと相まって、血栓溶解薬の需要を押し上げています。

尿や便の異常な出血、傷や切り傷からの過剰な出血、血栓溶解薬に対するアレルギー反応、低血圧、血栓溶解薬のその他の副作用のために、注意深く監督された投与が必要です。まれに、血栓溶解薬を使用せずに血栓をコントロールする他の選択肢がある場合があります。例えば、深部静脈血栓症や肺塞栓症の場合、抗凝固薬（ヘパリンや直接経口抗凝固薬など）が主要な治療薬として使用されることがあります。補完療法の利用可能性は、血栓溶解薬の需要に影響を与える可能性があります。

血栓溶解薬市場の拡大は、経済成長、医療適用範囲の拡大、医療意識の高まりなど様々な要因によってもたらされます。医療支出の増加により、血栓溶解薬はより手頃な価格で入手しやすくなり、その結果需要が増加します。血栓溶解薬の有効性と安全性を評価するための継続的な調査と臨床試験が市場の拡大を後押ししています。医療のインフラが改善し、さまざまな地域で血栓症に対する意識が高まるにつれて、効果的な血栓溶解薬に対するニーズが高まっています。製薬会社は、手頃な価格で利用しやすい治療法を提供することで、こうした市場を発展させることができます。

COVID-19の流行は、血栓溶解薬市場を含む医療の多くの部分に大きな影響を与えています。COVID-19は主に呼吸器系に影響を及ぼしますが、さまざまな心血管系の問題を引き起こす可能性もあり、血栓溶解薬の需要や使用に影響を与える可能性があります。COVID-19は、深部静脈血栓症（DVT）、肺塞栓症、脳卒中などの障害を引き起こす可能性のある血栓形成の高いリスクと関連しています。研究では、COVID-19に関連する血栓形成の問題に対する、血栓溶解薬を含むさまざまな抗凝固療法の有効性が検討されています。これらの研究は、パンデミック後の市場力学と臨床実践に影響を与えると予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

• 市場の定義と範囲
• 主な調査結果
  • 影響要因
  • 主な投資機会
• ポーターのファイブフォース分析
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• COVID-19：市場への影響分析
• 平均販売価格
• 市場シェア分析
• ブランドシェア分析
• バリューチェーン分析
• 主要規制分析
• 特許情勢
• 規制ガイドライン
• 貿易データ分析

第4章 血栓溶解薬市場：製品別

• 概要
• 血栓溶解薬
• 抗血小板薬
• 抗凝固薬
• その他

第5章 血栓溶解薬市場：適応症別

• 概要
• 肺塞栓症
• 深部静脈血栓症
• 心房細動
• その他

第6章 血栓溶解薬市場：投与経路別

• 概要
• 経口
• 注射

第7章 血栓溶解薬市場：流通チャネル別

• 概要
• 病院薬局
• オンライン薬局
• 小売薬局

第8章 血栓溶解薬市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • その他アジア太平洋地域
• ラテンアメリカ・中東・アフリカ
  • ブラジル
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • その他ラテンアメリカ・中東・アフリカ

第9章 競合情勢

• イントロダクション
• 主要成功戦略
• 主要10企業の製品マッピング
• 競合ダッシュボード
• 競合ヒートマップ
• 主要企業のポジショニング、2022年

第10章 企業プロファイル

• Pfizer Inc.
• Johnson & Johnson Services Inc
• Sanofi
• Dr. Reddy's Laboratories
• Bayer AG
• Boehringer Ingelheim Gmbh
• Genentech Inc.
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.
• Merck & Co

LIST OF TABLES

• TABLE 01. GLOBAL CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 02. CLOT BUSTING DRUGS MARKET FOR THROMBOLYTIC DRUGS, BY REGION, 2022-2032 ($MILLION)
• TABLE 03. CLOT BUSTING DRUGS MARKET FOR ANTI-PLATELET DRUGS, BY REGION, 2022-2032 ($MILLION)
• TABLE 04. CLOT BUSTING DRUGS MARKET FOR ANTICOAGULANTS, BY REGION, 2022-2032 ($MILLION)
• TABLE 05. CLOT BUSTING DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
• TABLE 06. GLOBAL CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 07. CLOT BUSTING DRUGS MARKET FOR PULMONARY EMBOLISM, BY REGION, 2022-2032 ($MILLION)
• TABLE 08. CLOT BUSTING DRUGS MARKET FOR DEEP VEIN THROMBOSIS, BY REGION, 2022-2032 ($MILLION)
• TABLE 09. CLOT BUSTING DRUGS MARKET FOR ATRIAL FIBRILLATION, BY REGION, 2022-2032 ($MILLION)
• TABLE 10. CLOT BUSTING DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
• TABLE 11. GLOBAL CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 12. CLOT BUSTING DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
• TABLE 13. CLOT BUSTING DRUGS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
• TABLE 14. GLOBAL CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 15. CLOT BUSTING DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
• TABLE 16. CLOT BUSTING DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
• TABLE 17. CLOT BUSTING DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
• TABLE 18. CLOT BUSTING DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
• TABLE 19. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 20. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 21. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 22. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 23. NORTH AMERICA CLOT BUSTING DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 24. U.S. CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 25. U.S. CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 26. U.S. CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 27. U.S. CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 28. CANADA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 29. CANADA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 30. CANADA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 31. CANADA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 32. MEXICO CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 33. MEXICO CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 34. MEXICO CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 35. MEXICO CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 36. EUROPE CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 37. EUROPE CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 38. EUROPE CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 39. EUROPE CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 40. EUROPE CLOT BUSTING DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 41. GERMANY CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 42. GERMANY CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 43. GERMANY CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 44. GERMANY CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 45. UK CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 46. UK CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 47. UK CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 48. UK CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 49. FRANCE CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 50. FRANCE CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 51. FRANCE CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 52. FRANCE CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 53. SPAIN CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 54. SPAIN CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 55. SPAIN CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 56. SPAIN CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 57. ITALY CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 58. ITALY CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 59. ITALY CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 60. ITALY CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 61. REST OF EUROPE CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 62. REST OF EUROPE CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 63. REST OF EUROPE CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 64. REST OF EUROPE CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 65. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 66. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 67. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 68. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 69. ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 70. CHINA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 71. CHINA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 72. CHINA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 73. CHINA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 74. JAPAN CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 75. JAPAN CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 76. JAPAN CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 77. JAPAN CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 78. INDIA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 79. INDIA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 80. INDIA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 81. INDIA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 82. SOUTH KOREA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 83. SOUTH KOREA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 84. SOUTH KOREA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 85. SOUTH KOREA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 86. AUSTRALIA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 87. AUSTRALIA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 88. AUSTRALIA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 89. AUSTRALIA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 90. REST OF ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 91. REST OF ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 92. REST OF ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 93. REST OF ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 94. LAMEA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 95. LAMEA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 96. LAMEA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 97. LAMEA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 98. LAMEA CLOT BUSTING DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 99. BRAZIL CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 100. BRAZIL CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 101. BRAZIL CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 102. BRAZIL CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 103. SAUDI ARABIA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 104. SAUDI ARABIA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 105. SAUDI ARABIA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 106. SAUDI ARABIA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 107. UNITED ARAB EMIRATES CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 108. UNITED ARAB EMIRATES CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 109. UNITED ARAB EMIRATES CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 110. UNITED ARAB EMIRATES CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 111. SOUTH AFRICA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 112. SOUTH AFRICA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 113. SOUTH AFRICA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 114. SOUTH AFRICA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 115. REST OF LAMEA CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
• TABLE 116. REST OF LAMEA CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
• TABLE 117. REST OF LAMEA CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
• TABLE 118. REST OF LAMEA CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 119. PFIZER INC.: KEY EXECUTIVES
• TABLE 120. PFIZER INC.: COMPANY SNAPSHOT
• TABLE 121. JOHNSON & JOHNSON SERVICES INC: KEY EXECUTIVES
• TABLE 122. JOHNSON & JOHNSON SERVICES INC: COMPANY SNAPSHOT
• TABLE 123. SANOFI: KEY EXECUTIVES
• TABLE 124. SANOFI: COMPANY SNAPSHOT
• TABLE 125. DR. REDDY'S LABORATORIES: KEY EXECUTIVES
• TABLE 126. DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT
• TABLE 127. BAYER AG: KEY EXECUTIVES
• TABLE 128. BAYER AG: COMPANY SNAPSHOT
• TABLE 129. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
• TABLE 130. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
• TABLE 131. GENENTECH INC.: KEY EXECUTIVES
• TABLE 132. GENENTECH INC.: COMPANY SNAPSHOT
• TABLE 133. ELI LILLY AND COMPANY: KEY EXECUTIVES
• TABLE 134. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
• TABLE 135. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
• TABLE 136. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
• TABLE 137. MERCK & CO: KEY EXECUTIVES
• TABLE 138. MERCK & CO: COMPANY SNAPSHOT

LIST OF FIGURES

• FIGURE 01. CLOT BUSTING DRUGS MARKET, 2022-2032
• FIGURE 02. SEGMENTATION OF CLOT BUSTING DRUGS MARKET, 2022-2032
• FIGURE 03. TOP INVESTMENT POCKETS IN CLOT BUSTING DRUGS MARKET (2023-2032)
• FIGURE 04. BARGAINING POWER OF SUPPLIERS
• FIGURE 05. BARGAINING POWER OF BUYERS
• FIGURE 06. THREAT OF SUBSTITUTION
• FIGURE 07. THREAT OF SUBSTITUTION
• FIGURE 08. COMPETITIVE RIVALRY
• FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCLOT BUSTING DRUGS MARKET
• FIGURE 10. IMPACT OF KEY REGULATION: CLOT BUSTING DRUGS MARKET
• FIGURE 11. PATENT ANALYSIS BY COMPANY
• FIGURE 12. PATENT ANALYSIS BY COUNTRY
• FIGURE 13. REGULATORY GUIDELINES: CLOT BUSTING DRUGS MARKET
• FIGURE 13. CLOT BUSTING DRUGS MARKET, BY PRODUCT, 2022(%)
• FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR THROMBOLYTIC DRUGS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR ANTI-PLATELET DRUGS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR ANTICOAGULANTS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 18. CLOT BUSTING DRUGS MARKET, BY INDICATION, 2022(%)
• FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR PULMONARY EMBOLISM, BY COUNTRY 2022 AND 2032(%)
• FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR DEEP VEIN THROMBOSIS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR ATRIAL FIBRILLATION, BY COUNTRY 2022 AND 2032(%)
• FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 23. CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
• FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
• FIGURE 25. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR INJECTABLE, BY COUNTRY 2022 AND 2032(%)
• FIGURE 26. CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
• FIGURE 27. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2022 AND 2032(%)
• FIGURE 28. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY 2022 AND 2032(%)
• FIGURE 29. COMPARATIVE SHARE ANALYSIS OF CLOT BUSTING DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY 2022 AND 2032(%)
• FIGURE 30. CLOT BUSTING DRUGS MARKET BY REGION, 2022
• FIGURE 31. U.S. CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 32. CANADA CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 33. MEXICO CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 34. GERMANY CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 35. UK CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 36. FRANCE CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 37. SPAIN CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 38. ITALY CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 39. REST OF EUROPE CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 40. CHINA CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 41. JAPAN CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 42. INDIA CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 43. SOUTH KOREA CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 44. AUSTRALIA CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 45. REST OF ASIA-PACIFIC CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 46. BRAZIL CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 47. SAUDI ARABIA CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 48. UNITED ARAB EMIRATES CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 49. SOUTH AFRICA CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 50. REST OF LAMEA CLOT BUSTING DRUGS MARKET, 2022-2032 ($MILLION)
• FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
• FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
• FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
• FIGURE 54. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 55. COMPETITIVE DASHBOARD
• FIGURE 56. COMPETITIVE HEATMAP: CLOT BUSTING DRUGS MARKET
• FIGURE 57. TOP PLAYER POSITIONING, 2022

According to a new report published by Allied Market Research, titled, "Clot Busting Drugs Market," The clot busting drugs market was valued at $28.6 billion in 2022, and is estimated to reach $60 billion by 2032, growing at a CAGR of 8.2% from 2023 to 2032.

Clot-busting drugs, also known as thrombolytic agents or fibrinolytic drugs, are medications used to dissolve blood clots in a medical condition called thrombosis. Thrombosis occurs when a blood clot forms within a blood vessel, obstructing the flow of blood. TPA is a thrombolytic or clot buster drug which is used to break up the clot that is causing a blockage or disruption in the flow of blood to the brain and aids in the restoration of blood flow to the affected part of the brain. Anticoagulants, such as heparin, warfarin, dabigatran, apixaban, and rivaroxaban, are medications that thin the blood and help to dissolve blood clots.

Treatment guidelines for cardiovascular disorders frequently need the use of clot-busting medicines in specific conditions.. Improved diagnostic procedures and increased awareness of the signs and symptoms of cardiovascular illnesses have resulted in earlier detection and treatment. To prevent harm in the future, early intervention typically includes the use of clot-busting medications. Overall, the rising prevalence of cardiovascular disorders, combined with innovations in treatment choices and increasing awareness, is boosting demand for clot busting drugs.

Careful and supervised administration is required due to unusual bleeding in the urine or stool, excessive bleeding from wounds or cuts, allergic reactions to clot buster medications, low blood pressure, and other side effects of clot busting medications. There may rarely be other options for controlling blood clots without the use of clot-busting drugs. For instance, in some situations of thrombosis of the deep veins or pulmonary embolism, anticoagulant medications (such as heparin or direct oral anticoagulants) may be used as the primary treatment. The availability of complementary therapies can affect the demand for clot-busting drugs.

The clot busting drugs market expansion is driven by various factors such as economic growth, increase in healthcare coverage, and rise in healthcare awareness. With increased healthcare spending, clot buster medications become more affordable and accessible, resulting in an increase in demand. Ongoing research and clinical trials to assess the efficacy and safety of clot buster medicines boosts the market expansion. As healthcare infrastructure improves and awareness of thrombotic disorders increases in various regions, there is a rising need for effective clot buster drugs. Pharmaceutical companies can tap into these markets by offering affordable and accessible treatment options.

The COVID-19 pandemic has had a substantial impact on many parts of healthcare, including the market for clot busting drugs. While COVID-19 predominantly affects the respiratory system, it can also cause a variety of cardiovascular problems, which may influence the demand for and use of clot-busting medications. COVID-19 has been linked to a higher risk of blood clot formation, which can result in disorders such as deep vein thrombosis (DVT), pulmonary embolism, and stroke. Studies have examined the effectiveness of different anticoagulant treatments, including clot-busting medications, in treating clotting issues associated with COVID-19. These investigations are expected to have an impact on market dynamics and clinical practices in the post-pandemic period.

The key players profiled in this report include: Pfizer Inc., Johnson & Johnson Services Inc, Sanofi, Dr. Reddy's Laboratories, Bayer AG, Boehringer Ingelheim Gmbh, Genentech Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., and Merck & Co.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the clot busting drugs market analysis from 2022 to 2032 to identify the prevailing clot busting drugs market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the clot busting drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global clot busting drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

• Thrombolytic Drugs
• Anti-Platelet Drugs
• Anticoagulants
• Others

By Indication

• Deep Vein Thrombosis
• Atrial Fibrillation
• Others
• Pulmonary Embolism

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • United Arab Emirates
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Bayer AG
• Boehringer Ingelheim Gmbh
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• Genentech Inc.
• Johnson & Johnson Services Inc
• Merck & Co
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities
• 3.5. COVID-19 Impact Analysis on the market
• 3.6. Average Selling Price
• 3.7. Market Share Analysis
• 3.8. Brand Share Analysis
• 3.9. Value Chain Analysis
• 3.10. Key Regulation Analysis
• 3.11. Patent Landscape
• 3.12. Regulatory Guidelines
• 3.13. Trade Data Analysis

CHAPTER 4: CLOT BUSTING DRUGS MARKET, BY PRODUCT

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Thrombolytic Drugs
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Anti-Platelet Drugs
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Anticoagulants
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Others
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: CLOT BUSTING DRUGS MARKET, BY INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Pulmonary Embolism
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Deep Vein Thrombosis
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Atrial Fibrillation
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: CLOT BUSTING DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Oral
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Injectable
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: CLOT BUSTING DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Hospital Pharmacy
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Online Pharmacy
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country
• 7.4. Retail Pharmacy
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by region
  • 7.4.3. Market share analysis by country

CHAPTER 8: CLOT BUSTING DRUGS MARKET, BY REGION

• 8.1. Overview
  • 8.1.1. Market size and forecast By Region
• 8.2. North America
  • 8.2.1. Key trends and opportunities
  • 8.2.2. Market size and forecast, by Product
  • 8.2.3. Market size and forecast, by Indication
  • 8.2.4. Market size and forecast, by Route of Administration
  • 8.2.5. Market size and forecast, by Distribution Channel
  • 8.2.6. Market size and forecast, by country
    • 8.2.6.1. U.S.
    • 8.2.6.1.1. Key market trends, growth factors and opportunities
    • 8.2.6.1.2. Market size and forecast, by Product
    • 8.2.6.1.3. Market size and forecast, by Indication
    • 8.2.6.1.4. Market size and forecast, by Route of Administration
    • 8.2.6.1.5. Market size and forecast, by Distribution Channel
    • 8.2.6.2. Canada
    • 8.2.6.2.1. Key market trends, growth factors and opportunities
    • 8.2.6.2.2. Market size and forecast, by Product
    • 8.2.6.2.3. Market size and forecast, by Indication
    • 8.2.6.2.4. Market size and forecast, by Route of Administration
    • 8.2.6.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6.3. Mexico
    • 8.2.6.3.1. Key market trends, growth factors and opportunities
    • 8.2.6.3.2. Market size and forecast, by Product
    • 8.2.6.3.3. Market size and forecast, by Indication
    • 8.2.6.3.4. Market size and forecast, by Route of Administration
    • 8.2.6.3.5. Market size and forecast, by Distribution Channel
• 8.3. Europe
  • 8.3.1. Key trends and opportunities
  • 8.3.2. Market size and forecast, by Product
  • 8.3.3. Market size and forecast, by Indication
  • 8.3.4. Market size and forecast, by Route of Administration
  • 8.3.5. Market size and forecast, by Distribution Channel
  • 8.3.6. Market size and forecast, by country
    • 8.3.6.1. Germany
    • 8.3.6.1.1. Key market trends, growth factors and opportunities
    • 8.3.6.1.2. Market size and forecast, by Product
    • 8.3.6.1.3. Market size and forecast, by Indication
    • 8.3.6.1.4. Market size and forecast, by Route of Administration
    • 8.3.6.1.5. Market size and forecast, by Distribution Channel
    • 8.3.6.2. UK
    • 8.3.6.2.1. Key market trends, growth factors and opportunities
    • 8.3.6.2.2. Market size and forecast, by Product
    • 8.3.6.2.3. Market size and forecast, by Indication
    • 8.3.6.2.4. Market size and forecast, by Route of Administration
    • 8.3.6.2.5. Market size and forecast, by Distribution Channel
    • 8.3.6.3. France
    • 8.3.6.3.1. Key market trends, growth factors and opportunities
    • 8.3.6.3.2. Market size and forecast, by Product
    • 8.3.6.3.3. Market size and forecast, by Indication
    • 8.3.6.3.4. Market size and forecast, by Route of Administration
    • 8.3.6.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6.4. Spain
    • 8.3.6.4.1. Key market trends, growth factors and opportunities
    • 8.3.6.4.2. Market size and forecast, by Product
    • 8.3.6.4.3. Market size and forecast, by Indication
    • 8.3.6.4.4. Market size and forecast, by Route of Administration
    • 8.3.6.4.5. Market size and forecast, by Distribution Channel
    • 8.3.6.5. Italy
    • 8.3.6.5.1. Key market trends, growth factors and opportunities
    • 8.3.6.5.2. Market size and forecast, by Product
    • 8.3.6.5.3. Market size and forecast, by Indication
    • 8.3.6.5.4. Market size and forecast, by Route of Administration
    • 8.3.6.5.5. Market size and forecast, by Distribution Channel
    • 8.3.6.6. Rest of Europe
    • 8.3.6.6.1. Key market trends, growth factors and opportunities
    • 8.3.6.6.2. Market size and forecast, by Product
    • 8.3.6.6.3. Market size and forecast, by Indication
    • 8.3.6.6.4. Market size and forecast, by Route of Administration
    • 8.3.6.6.5. Market size and forecast, by Distribution Channel
• 8.4. Asia-Pacific
  • 8.4.1. Key trends and opportunities
  • 8.4.2. Market size and forecast, by Product
  • 8.4.3. Market size and forecast, by Indication
  • 8.4.4. Market size and forecast, by Route of Administration
  • 8.4.5. Market size and forecast, by Distribution Channel
  • 8.4.6. Market size and forecast, by country
    • 8.4.6.1. China
    • 8.4.6.1.1. Key market trends, growth factors and opportunities
    • 8.4.6.1.2. Market size and forecast, by Product
    • 8.4.6.1.3. Market size and forecast, by Indication
    • 8.4.6.1.4. Market size and forecast, by Route of Administration
    • 8.4.6.1.5. Market size and forecast, by Distribution Channel
    • 8.4.6.2. Japan
    • 8.4.6.2.1. Key market trends, growth factors and opportunities
    • 8.4.6.2.2. Market size and forecast, by Product
    • 8.4.6.2.3. Market size and forecast, by Indication
    • 8.4.6.2.4. Market size and forecast, by Route of Administration
    • 8.4.6.2.5. Market size and forecast, by Distribution Channel
    • 8.4.6.3. India
    • 8.4.6.3.1. Key market trends, growth factors and opportunities
    • 8.4.6.3.2. Market size and forecast, by Product
    • 8.4.6.3.3. Market size and forecast, by Indication
    • 8.4.6.3.4. Market size and forecast, by Route of Administration
    • 8.4.6.3.5. Market size and forecast, by Distribution Channel
    • 8.4.6.4. South Korea
    • 8.4.6.4.1. Key market trends, growth factors and opportunities
    • 8.4.6.4.2. Market size and forecast, by Product
    • 8.4.6.4.3. Market size and forecast, by Indication
    • 8.4.6.4.4. Market size and forecast, by Route of Administration
    • 8.4.6.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6.5. Australia
    • 8.4.6.5.1. Key market trends, growth factors and opportunities
    • 8.4.6.5.2. Market size and forecast, by Product
    • 8.4.6.5.3. Market size and forecast, by Indication
    • 8.4.6.5.4. Market size and forecast, by Route of Administration
    • 8.4.6.5.5. Market size and forecast, by Distribution Channel
    • 8.4.6.6. Rest of Asia-Pacific
    • 8.4.6.6.1. Key market trends, growth factors and opportunities
    • 8.4.6.6.2. Market size and forecast, by Product
    • 8.4.6.6.3. Market size and forecast, by Indication
    • 8.4.6.6.4. Market size and forecast, by Route of Administration
    • 8.4.6.6.5. Market size and forecast, by Distribution Channel
• 8.5. LAMEA
  • 8.5.1. Key trends and opportunities
  • 8.5.2. Market size and forecast, by Product
  • 8.5.3. Market size and forecast, by Indication
  • 8.5.4. Market size and forecast, by Route of Administration
  • 8.5.5. Market size and forecast, by Distribution Channel
  • 8.5.6. Market size and forecast, by country
    • 8.5.6.1. Brazil
    • 8.5.6.1.1. Key market trends, growth factors and opportunities
    • 8.5.6.1.2. Market size and forecast, by Product
    • 8.5.6.1.3. Market size and forecast, by Indication
    • 8.5.6.1.4. Market size and forecast, by Route of Administration
    • 8.5.6.1.5. Market size and forecast, by Distribution Channel
    • 8.5.6.2. Saudi Arabia
    • 8.5.6.2.1. Key market trends, growth factors and opportunities
    • 8.5.6.2.2. Market size and forecast, by Product
    • 8.5.6.2.3. Market size and forecast, by Indication
    • 8.5.6.2.4. Market size and forecast, by Route of Administration
    • 8.5.6.2.5. Market size and forecast, by Distribution Channel
    • 8.5.6.3. United Arab Emirates
    • 8.5.6.3.1. Key market trends, growth factors and opportunities
    • 8.5.6.3.2. Market size and forecast, by Product
    • 8.5.6.3.3. Market size and forecast, by Indication
    • 8.5.6.3.4. Market size and forecast, by Route of Administration
    • 8.5.6.3.5. Market size and forecast, by Distribution Channel
    • 8.5.6.4. South Africa
    • 8.5.6.4.1. Key market trends, growth factors and opportunities
    • 8.5.6.4.2. Market size and forecast, by Product
    • 8.5.6.4.3. Market size and forecast, by Indication
    • 8.5.6.4.4. Market size and forecast, by Route of Administration
    • 8.5.6.4.5. Market size and forecast, by Distribution Channel
    • 8.5.6.5. Rest of LAMEA
    • 8.5.6.5.1. Key market trends, growth factors and opportunities
    • 8.5.6.5.2. Market size and forecast, by Product
    • 8.5.6.5.3. Market size and forecast, by Indication
    • 8.5.6.5.4. Market size and forecast, by Route of Administration
    • 8.5.6.5.5. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

• 10.1. Pfizer Inc.
  • 10.1.1. Company overview
  • 10.1.2. Key Executives
  • 10.1.3. Company snapshot
• 10.2. Johnson & Johnson Services Inc
  • 10.2.1. Company overview
  • 10.2.2. Key Executives
  • 10.2.3. Company snapshot
• 10.3. Sanofi
  • 10.3.1. Company overview
  • 10.3.2. Key Executives
  • 10.3.3. Company snapshot
• 10.4. Dr. Reddy's Laboratories
  • 10.4.1. Company overview
  • 10.4.2. Key Executives
  • 10.4.3. Company snapshot
• 10.5. Bayer AG
  • 10.5.1. Company overview
  • 10.5.2. Key Executives
  • 10.5.3. Company snapshot
• 10.6. Boehringer Ingelheim Gmbh
  • 10.6.1. Company overview
  • 10.6.2. Key Executives
  • 10.6.3. Company snapshot
• 10.7. Genentech Inc.
  • 10.7.1. Company overview
  • 10.7.2. Key Executives
  • 10.7.3. Company snapshot
• 10.8. Eli Lilly and Company
  • 10.8.1. Company overview
  • 10.8.2. Key Executives
  • 10.8.3. Company snapshot
• 10.9. Sun Pharmaceutical Industries Ltd.
  • 10.9.1. Company overview
  • 10.9.2. Key Executives
  • 10.9.3. Company snapshot
• 10.10. Merck & Co
  • 10.10.1. Company overview
  • 10.10.2. Key Executives
  • 10.10.3. Company snapshot